NO20074509L - Kombinasjon av organiske forbindelser - Google Patents

Kombinasjon av organiske forbindelser

Info

Publication number
NO20074509L
NO20074509L NO20074509A NO20074509A NO20074509L NO 20074509 L NO20074509 L NO 20074509L NO 20074509 A NO20074509 A NO 20074509A NO 20074509 A NO20074509 A NO 20074509A NO 20074509 L NO20074509 L NO 20074509L
Authority
NO
Norway
Prior art keywords
pharmaceutically acceptable
acceptable salt
combination
angiotensin
organic compounds
Prior art date
Application number
NO20074509A
Other languages
English (en)
Norwegian (no)
Inventor
Randy Lee Webb
Gary Michael Ksander
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36793671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20074509(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20074509L publication Critical patent/NO20074509L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20074509A 2005-02-11 2007-09-06 Kombinasjon av organiske forbindelser NO20074509L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US65232505P 2005-02-11 2005-02-11
US65510205P 2005-02-22 2005-02-22
US67009005P 2005-04-11 2005-04-11
PCT/US2006/004401 WO2006086456A2 (en) 2005-02-11 2006-02-09 Combination of organic compounds

Publications (1)

Publication Number Publication Date
NO20074509L true NO20074509L (no) 2007-11-12

Family

ID=36793671

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074509A NO20074509L (no) 2005-02-11 2007-09-06 Kombinasjon av organiske forbindelser

Country Status (18)

Country Link
US (1) US20080119557A1 (enExample)
EP (1) EP1863467A2 (enExample)
JP (1) JP2008530101A (enExample)
KR (1) KR20070102544A (enExample)
AR (1) AR053809A1 (enExample)
AU (1) AU2006212772B2 (enExample)
BR (1) BRPI0606996A2 (enExample)
CA (1) CA2596485A1 (enExample)
GT (1) GT200600055A (enExample)
IL (1) IL184426A0 (enExample)
MA (1) MA29326B1 (enExample)
MY (1) MY146830A (enExample)
NO (1) NO20074509L (enExample)
NZ (1) NZ556275A (enExample)
PE (1) PE20060999A1 (enExample)
TN (1) TNSN07312A1 (enExample)
TW (1) TW200716081A (enExample)
WO (1) WO2006086456A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE551052T1 (de) * 2004-10-08 2012-04-15 Novartis Ag Verwendung von reninhemmern zur prävention oder behandlung von diastolischer dysfunktion oder diastolischer herzinsuffizienz
WO2007051007A2 (en) * 2005-10-28 2007-05-03 Novartis Ag Combination of antihypertensives with cholesterol-lowering agent
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
BRPI0806700A8 (pt) 2007-01-12 2019-01-22 Novartis Ag processo
TW200838501A (en) * 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
TWI406850B (zh) 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
JP2010538071A (ja) 2007-09-07 2010-12-09 セラヴァンス， インコーポレーテッド 二重作用性降圧剤
US20110033533A1 (en) * 2007-09-28 2011-02-10 Jean-Claude Bianchi Galenical formulations of organic compounds
WO2009040427A1 (en) * 2007-09-28 2009-04-02 Novartis Ag Galenical formulations of organic compounds
AR066168A1 (es) * 2007-09-28 2009-07-29 Novartis Ag Formulaciones galenicas de compuestos organicos
WO2009076288A1 (en) 2007-12-11 2009-06-18 Theravance, Inc. Dual-acting benzoimidazole derivative and their use as antihypertensive agents
WO2009134741A1 (en) 2008-04-29 2009-11-05 Theravance, Inc. Dual-acting antihypertensive agents
US8569381B2 (en) 2008-05-23 2013-10-29 Targacept, Inc. Combination therapy for the management of hypertension
JP2010031006A (ja) * 2008-07-17 2010-02-12 Novartis Ag 有機化合物の使用
WO2010011821A2 (en) 2008-07-24 2010-01-28 Theravance, Inc. Dual-acting antihypertensive agents
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
MX2011009844A (es) * 2009-03-20 2011-09-29 Novartis Ag Composicion farmaceutica que comprende alisquireno.
CN102574801B (zh) * 2009-05-28 2016-04-27 诺华股份有限公司 作为脑啡肽酶抑制剂的取代的氨基丙酸衍生物
CN102448928B (zh) 2009-05-28 2014-10-01 诺华股份有限公司 作为中性溶酶(neprilysin)抑制剂的取代的氨基丁酸衍生物
WO2011005674A1 (en) 2009-07-07 2011-01-13 Theravance, Inc. Dual-acting pyrazole antihypertensive agents
WO2011011232A1 (en) 2009-07-22 2011-01-27 Theravance, Inc. Dual-acting oxazole antihypertensive agents
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
EP2526095A1 (en) 2010-01-19 2012-11-28 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
RU2588572C2 (ru) 2010-08-23 2016-07-10 Новартис Аг Способ получения промежуточных соединений для получения ингибиторов nep
US8877815B2 (en) * 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) * 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
HUE054885T2 (hu) * 2012-08-24 2021-10-28 Novartis Ag NEP-inhibitorok szívpitvari megnagyobbodással vagy átrendezõdéssel jellemzett betegségek kezelésére
JP6301371B2 (ja) 2013-02-14 2018-04-11 ノバルティス アーゲー インビボ効力が改善されたｎｅｐ阻害剤としての置換ビスフェニルブタン酸誘導体
JP6295277B2 (ja) 2013-02-14 2018-03-14 ノバルティス アーゲー Ｎｅｐ（中性エンドペプチダーゼ）阻害剤としての置換ビスフェニルブタン酸ホスホン酸誘導体
CN105348209B (zh) 2015-12-09 2017-12-26 浙江天宇药业股份有限公司 一种抗心衰药lcz696的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013564A1 (en) * 1991-02-06 1992-08-20 Schering Corporation Combination of an angiotensin ii antagonist or renin inhibitor with a neutral endopeptidase inhibitor
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
DE19750529A1 (de) * 1997-11-14 1999-05-20 Basf Ag Neue heterocyclisch substituierte alpha-Hydroxycarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten
US6506785B2 (en) * 1998-05-22 2003-01-14 Pfizer, Inc. Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US7468390B2 (en) * 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
PT1467728E (pt) * 2002-01-17 2007-11-14 Novartis Ag Composições farmacêuticas compreendendo valsartan e inibidores da nep
EP2316488A1 (en) * 2002-05-17 2011-05-04 Novartis AG Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
CL2004000544A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
US20040214804A1 (en) * 2003-04-25 2004-10-28 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-obesity agent

Also Published As

Publication number Publication date
AR053809A1 (es) 2007-05-23
TW200716081A (en) 2007-05-01
AU2006212772A1 (en) 2006-08-17
CA2596485A1 (en) 2006-08-17
MA29326B1 (fr) 2008-03-03
MY146830A (en) 2012-09-28
TNSN07312A1 (en) 2008-12-31
IL184426A0 (en) 2007-10-31
PE20060999A1 (es) 2006-11-21
WO2006086456A3 (en) 2007-11-15
KR20070102544A (ko) 2007-10-18
US20080119557A1 (en) 2008-05-22
BRPI0606996A2 (pt) 2009-07-28
JP2008530101A (ja) 2008-08-07
GT200600055A (es) 2006-09-07
NZ556275A (en) 2011-04-29
EP1863467A2 (en) 2007-12-12
WO2006086456A2 (en) 2006-08-17
AU2006212772B2 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
NO20074509L (no) Kombinasjon av organiske forbindelser
NO20075344L (no) Metforminbaserte fremgangsmater og utforminger for behandling av kronisk forstoppelse
WO2008050329A3 (en) Novel sirnas and methods of use thereof
WO2005070463A3 (en) Compositions comprising (s)-amlodipine malate and an angiotensin receptor blocker and methods of their use
NO20061640L (no) Hurtig opplosningspreparat av en kalsiumreseptiraktiv forbindelse
NO20070910L (no) Pyrrolderivater som farmasoytiske middel
EP2178869A4 (en) INDOL COMPOUNDS AS AN INHIBITORS OF CELL NECROSIS
NO20044562L (no) Fremgangsmater for behandling av tarmslyng
WO2006044694A3 (en) Methods and compositions for treating a disease condition in a subject
WO2007088489A3 (en) Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
WO2007120972A3 (en) Method to treat sickle cell disease
BRPI0519124A2 (pt) composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço
WO2006059245A3 (en) Compounds for the treatment of cns and amyloid associated diseases
WO2008059370A3 (en) Substituted bicyclocarboxyamide compounds
JP2008508279A5 (enExample)
WO2007092469A3 (en) Combination of organic compounds
WO2008050199A3 (en) Substituted phenylmethyl bicyclocarboxyamide compounds
WO2007056324A3 (en) Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent
WO2006020680A3 (en) Heterocyclic compounds as pharmaceutical agents
CL2003002292A1 (es) Composicion farmaceutica que comprende un compuesto derivado de acido carboxilico, uno o mas compuestos terapeuticamente activos y un diluyente farmacologicamente aceptable; y su uso para tratar una enfermedad inflamatoria.
WO2003051290A3 (en) Treating b-cell mediated diseases by modulating dr6 activity
WO2006061715A3 (en) Methylene inhibitors of matrix metalloproteinase
NO20070127L (no) Fremgangsmate for behandling av granuloma annulare eller sarkoid
MX2007004020A (es) Uso de inhibidores de renina para la prevencion o tratamiento de disfuncion diastolica o falla cardiaca diastolica.
WO2006031782A3 (en) Salvinorin derivatives as opioid receptor ligands

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application